- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02388776
Use of Rotational Thromboelastometry (ROTEM) to Characterize Coagulation Abnormalities in Burn Patients
Use of Rotational Thromboelastometry (ROTEM) to Characterize Coagulation Abnormalities in Burn Patients: A Prospective Pilot Study
Study Overview
Detailed Description
Specific aims of this pilot study are to use bedside blood analysis with ROTEM in severe burn patients to provide preliminary information on the nature of coagulation abnormalities and to compare subject ROTEM coagulation profiles within 24 hours of burn injury (day 1) and on days 2, 3, 5, 7, 14 and 21 after burn injury. Investigators hypothesize that ROTEM analysis will detect a pattern of impaired coagulation in severely burned patients.
ROTEM analysis:
A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve. Blood will be obtained for ROTEM/ fibrinogen levels from each subject seven times during their hospital admission: once within 24 hours of burn injury (day 1), and on days 2, 3, 5, 7, 14 and 21. For each sample, 5.4 mL of whole blood will be collected into 2 citrated tubes (2.7 mL in each tube). For all subjects, both pediatric and adult, blood will be collected via an indwelling catheter (arterial or central line). One 2.7 ml tube will be used for ROTEM analysis. The amount of blood is in accordance with the acceptable limit of ROTEM analysis. ROTEM testing will be performed according to the manufacturer's instructions using test kit reagents. Members of the clinical research team who have been trained and certified to use the ROTEM device will perform the appropriate ROTEM tests. The second 2.7 mL citrated tube will be used to measure fibrinogen level, using the automated central laboratory device in hospital.
In this interventional study, the ROTEM data will be blinded to the treating Burn ICU physicians and will have no effect on standard perioperative and ICU treatment. The ROTEM machine will be located in a designated spot outside of the ICU, out of view of the treating clinicians. Thus, volume replacement, thrombosis prophylaxis, and other management (including blood product transfusions) will be performed according to existing protocols.
Demographic information will be de-identified, but will include demographics (age, sex) and each subject's medical and surgical history, burn injury type (thermal, chemical, electrical, inhalational, plus/minus additional injury - i.e. Trauma/TBI, etc) and percent Total Body Surface Area (TBSA) as diagrammed by the Burn ICU on admission, medications (specifically, form of venous thromboembolism prophylaxis as prescribed by ICU physicians during the study period), weight, vital signs, dates of surgical intervention (bedside escharotomies and OR procedures), dates and types of blood product administration, fluid balance per day, number of days intubated, number of ICU days, hospital LOS, mortality, and ISS. Laboratory values: (on days 1, 2, 3, 5, 7, 14, and 21) will include fibrinogen, PT, INR, aPTT, and CBC when available as standard of care.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Weill Cornell Medical College
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Consecutive patients admitted to NYPH with 15% TBSA burn or greater.
- Patients with vascular access catheters (arterial or central line) placed within 24 hours of burn injury
- Males and females
- Ages >3 years or >15 kg
- Informed verbal consent obtained from the patient or the patient's designated health care proxy (DHCP). In the case of minors, assent and informed verbal consent obtained from at least one parent or guardian.
Exclusion Criteria:
- Known pre-existing hemostatic abnormalities
- Ages < 3 years or weight < 15 kg
- Intake of anticoagulants or antiplatelet aggregation inhibitors prior to burn
- Pregnant patients
- Patients with delayed presentation (greater than 24 hours after burn injury)
- Inclusion in another clinical research study
- Refusal or inability of patient or patient's DHCP to consent in English.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ROTEM
Clinical burn ICU Inpatients receiving blood draws for ROTEM analysis and fibrinogen levels.
|
A blood sample and reagents are placed into a small cup.
A pin suspended from a wire is immersed into the sample.
The pin rotates back and forth at a fixed angle.
The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically.
Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line.
As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot.
Graphically, this is represented as a symmetrical widening of the curve.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Coagulation Parameters
Time Frame: 21 days
|
To compare ROTEM coagulation parameters involving fibrin contribution to clot formation (FIBTEM) between patients on admission/enrollment (day 1), and on days 2, 3, 5, 7, 14 and 21 after burn injury to see if expected hypercoagulability shows evidence of resolution.
|
21 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Predictive Value of ROTEM Data
Time Frame: 21 days
|
To assess whether ROTEM abnormalities correlate with allogenic blood product administration by blinded ICU physicians
|
21 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Christine Lennon, MD, Weill Medical College of Cornell University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1404014977
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Burn
-
Xequel Bio, Inc.United States Department of DefenseWithdrawnThermal Burn | Second Degree Burn
-
Indonesia UniversityRecruitingBurn Degree Second | Burn Degree ThirdIndonesia
-
XenoTherapeutics, Inc.Joseph M. Still Research Foundation, Inc.Active, not recruitingWound Heal | Thermal Burn | Burn Degree Second | Burns Degree Third | Burn (Disorder)United States
-
University Hospital Schleswig-HolsteinUniversity of LuebeckRecruitingSecond-degree Burn | Third-Degree BurnGermany
-
General Electric ResearchRecruitingBurn Wound | 2nd Degree Burn of the SkinUnited States
-
University Hospital, LinkoepingCompletedBurn Scar | Burns | Burn Second DegreeSweden
-
University of AlbertaRecruitingBurn Degree Second | Burn; Multiple Body Regions, Max. Second Degree | Third-Degree BurnCanada
-
S.K. Lerik General HospitalCompletedBurn Scar | Burns | Burn Degree Second | Electrical BurnIndonesia
-
Regenera Pharma LtdWithdrawnPartial Thickness Burn | Second Degree Burn Less Than 5%TBSAIsrael
-
First Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
Clinical Trials on ROTEM
-
Tem Innovations GmbHUnknownBlood Coagulation DisordersUnited States, Austria, Switzerland
-
Weill Medical College of Cornell UniversityTerminatedCoagulopathyUnited States
-
Samsung Medical CenterUnknownPostoperative Hemorrhage | Coagulation Defect; Bleeding | Other Functional Disturbances Following Cardiac SurgeryKorea, Republic of
-
Seoul National University Bundang HospitalCompletedPlacenta Accreta | Placenta Previa | Placenta Percreta | Placenta IncretaKorea, Republic of
-
Tampere University HospitalCSL BehringCompletedAneurysmatic Subarachnoid HaemorrhageFinland
-
University of UtahEnrolling by invitationPlacenta Accreta
-
AHEPA University HospitalCompletedCoagulation Disorder | Extracorporeal Circulation; Complications | Extracorporeal Circulation of Blood; ThrombocytopeniaGreece
-
Entegrion, Inc.UnknownHemostasis MonitoringUnited States
-
Johann Wolfgang Goethe University HospitalHemoSonics LLCTerminatedHemorrhage | BleedingGermany